Liquidia Corporation Common Stock vs Roundhill Magnificent Seven ETF — how do they compare? Liquidia Corporation Common Stock trades at $34.58 (market cap $2.40B), while Roundhill Magnificent Seven ETF trades at $72.25 (market cap $5.89B). The key difference: Roundhill Magnificent Seven ETF is far larger — about 2.5× Liquidia Corporation Common Stock's market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Roundhill Magnificent Seven ETF for 35 Days on average.
| LQDA | MAGS | |
|---|---|---|
Market Cap | $2.40B | $5.89B |
Volume | 2,857,547 | 3,080,349 |
Sector | Health | Sector/Thematic |
52-Week High | $91.03 | $74.30 |
52-Week Low | $22.02 | $55.39 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $2.30B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MAGS, the Roundhill Magnificent Seven ETF, trades at $74.30, up 0.43% on the day, with a bullish technical signal driven by moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech stocks, though it has underperformed the S&P 500 in 2026 with a modest 2% year-to-date gain. Recent news highlights the group's focus on AI growth but notes a potential shift in market leadership away from the concentrated 'Magnificent Seven' theme.
The outlook for MAGS hinges on the continued AI-driven performance of its holdings, but risks include high concentration, valuation concerns, and market rotation. Investor sentiment is mixed, with some analysts advocating for the basket approach while others warn of fragmentation. Upside potential exists if the mega-caps reassert dominance, but diversification pressures pose a headwind.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →